INFLAMMASOMES AND INTERLEUKIN-18 SIGNALLING: NOVEL BIOMARKERS AND THERAPEUTIC TARGETS FOR KIDNEY DISEASE

炎症小体和白细胞介素 18 信号传导：肾脏疾病的新型生物标志物和治疗靶点

• 批准号: nhmrc : GNT1143674
• 负责人: A/Pr Ashley Mansell
• 金额: $ 100.33万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/inflammasomes-interleukin-18-kidney-disease/1348547
• 关键词: INFLAMMASOMES; INTERLEUKIN; 18; SIGNALLING; NOVEL

Chronic kidney disease (CKD) is a major health problem. There is no cure for CKD and current therapies merely slow its progression. Thus for many patients, dialysis or kidney transplant is an inevitable outcome. We have evidence that a protein called interleukin-18 (IL-18) is a key mediator of kidney damage in CKD. Here we will explore how IL-18 causes kidney damage and whether IL-18 may be used as a diagnostic for early detection of CKD, and a target for more effective therapies to treat CKD.

慢性肾脏疾病（CKD）是一个主要的健康问题。慢性肾病无法治愈，目前的治疗方法只是减缓其进展。因此，对许多患者来说，透析或肾移植是不可避免的结果。我们有证据表明，一种名为白介素-18 （IL-18）的蛋白质是CKD肾脏损伤的关键介质。在这里，我们将探讨IL-18如何引起肾脏损害，以及IL-18是否可以用作CKD早期检测的诊断，以及更有效治疗CKD的靶点。